Expertise in
17
conditions

Dr. Stephan A. Grupp

Hematology | Oncology
Office
3401 Civic Center Blvd, 
Philadelphia, PA 
Expertise in
17
conditions
Office
3401 Civic Center Blvd, 
Philadelphia, PA 

Overview

Stephan Grupp is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Grupp is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 236 peer reviewed articles and participating in 12 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatrics in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Geisinger
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Office
3401 Civic Center Blvd, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Grupp has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Biological
Study Drug: CD22 CAR-T Cells
Study Phase: Phase 1
Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure
Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Device
Study Phase: Not Applicable
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Enrollment Status: Completed
Publish Date: June 03, 2026
Intervention Type: Drug
Study Drug: Prednisone
Study Phase: Phase 2
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Enrollment Status: Completed
Publish Date: April 09, 2026
Intervention Type: Biological, Drug
Study Drugs: KTE-X19 Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1/Phase 2
UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Device
Study Phase: Phase 2
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)
A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: July 02, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

236 Total Publications

Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.
Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Referral may be required

Office

3500 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-3025
Languages Spoken:
English

John Maris is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Maris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Rhabdomyosarcoma.

Expertise in
15
conditions
Dr. Michael J. Fisher
Hematology | Oncology
Expertise in
15
conditions
Dr. Michael J. Fisher
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Michael Fisher is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Fisher is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Glioma, Gliomatosis Cerebri, and Osteotomy.

Frequently Asked Questions about Dr. Stephan A. Grupp

How do I make an appointment with Dr. Stephan A. Grupp?

You can book an appointment with Dr. Stephan A. Grupp by calling their office at 215-590-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephan A. Grupp a top-rated expert for Hepatic Venoocclusive Disease with Immunodeficiency?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephan A. Grupp is classified as an Elite expert for Hepatic Venoocclusive Disease with Immunodeficiency, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephan A. Grupp specialize in?

While Dr. Stephan A. Grupp is a Hematology, they have specific expertise in Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Stephan A. Grupp participate in research or clinical trials?

Yes. Dr. Stephan A. Grupp has published 236 articles and abstracts on conditions like Hepatic Venoocclusive Disease with Immunodeficiency. You can view a list of Dr. Stephan A. Grupp's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephan A. Grupp accept my insurance?

Dr. Stephan A. Grupp accepts most major insurance plans, including Geisinger and Medicaid. We recommend calling the office directly at 215-590-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grupp's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile